News

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington’s disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlle

Yahoo·13:03ALNY

Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case

SeekingAlpha·05:16ALNY

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

CAMBRIDGE, Mass., October 23, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (

Yahoo·03:45ALNY

Alnylam Says Phase 1b Brezosiran Study Showed Dose-Dependent CSF Mutant Huntingtin Reductions, Up To 83% Individually, No Dose-Dependent Safety Signals; Pivotal Study Planned 2027 Pending Regulatory Alignment

- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice

Benzinga·23:46ALNY

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00ALNY

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

This beaten-down biotech has a better story than its stock chart suggests.

Yahoo·05:04ALNY

Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases. At about $31 billion, the stock features on our list of 9 New Contenders for the S&P 500 Index. It stands out as a rare large biotech that has turned sustainably profitable under standard […]

Yahoo·13:33ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum

Alnylam shows strong growth, industry-cheap valuation, and solid health, fitting an affordable growth strategy despite rich absolute valuation.

ChartMill·08:51ALNY

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

CAMBRIDGE, Mass., October 15, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open.

Yahoo·08:00ALNY

Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?

Is ALNY a good stock to buy? We came across a bullish thesis on Alnylam Pharmaceuticals, Inc. on Astute Optics – US’s Substack. The thesis was published on September 11th, when the stock was trading at $248.68, and ALNY lost 8.70% since then. The decline appears to reflect lingering concerns about slower AMVUTTRA demand growth following the […]

Yahoo·12:43ALNY

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.

Benzinga·09:56ALNY

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.

Benzinga·06:47ALNY

If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 12.41% on an annualized basis producing an average annual return of 25.61%. Currently, Alnylam Pharmaceuticals has a market

Benzinga·13:30ALNY

Alnylam vs. Ionis: Here's the Better Bad-News Buy

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Yahoo·05:04ALNY

Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide

Alnylam Pharmaceuticals has seen a steep share price reset over the past year, which puts the focus squarely on whether the current valuation lines up with what the business earns. With recent legal scrutiny adding another layer of uncertainty, the key issue for investors is how much of that risk and opportunity is already reflected in the stock. The share price has fallen 50.9% over the past year, which raises the question of whether the current level now better reflects the company’s...

Yahoo·11:11ALNY

Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on an annualized basis producing an average annual return of 14.01%. Currently, Alnylam Pharmaceuticals has a market

Benzinga·08:15ALNY

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $369

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $375 to $369.

Benzinga·10:00ALNY

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.

SeekingAlpha·08:04ALNY

Alnylam Needs Stronger Amvuttra Execution To Justify More Upside

Alnylam at its current ~$255 valuation leaves limited upside without stronger commercial execution, especially for AMVUTTRA. Learn why ALNY stock is a hold.

SeekingAlpha·02:06ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga·02:34ALNY

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.

Yahoo·12:02ALNY

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri

Yahoo·21:01ALNY

RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics

RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a

Yahoo·06:42ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control September 17, 2026...

SeekingAlpha·12:08ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control - Slideshow

2026-09-17. The following slide deck was published by Alnylam Pharmaceuticals, Inc.

SeekingAlpha·08:59ALNY

Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?

Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...

Yahoo·15:18ALNY

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu

Yahoo·05:58

Alger Russell Innovation Index Updates for Third Quarter 2026

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, September 18, 2026, the Index will be rebalanced, and the following changes will be effective.

Yahoo·12:53

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsYvonne...

SeekingAlpha·09:11ALNY

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 15.67%. Currently, Alnylam Pharmaceuticals has a market

Benzinga·07:01ALNY

Here’s Why Alnylam Pharmaceuticals (ALNY) Declined

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

Yahoo·07:44ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 8:45 AM EDTCompany ParticipantsJohn Kennedy - Senior...

SeekingAlpha·07:55ALNY

Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy

170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Transthyretin Amyloidosis - Market Insight, Epidemiology, and Market Forecast - 2036" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of hATTR, its historical and forecasted epidemiology, and market trends

Yahoo·05:02ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech

Alnylam (NASDAQ:ALNY) passes the Affordable Growth screen with strong growth, reasonable valuation, solid profitability, and healthy financials.

ChartMill·04:04ALNY

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·12:30

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Benzinga·09:35

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

CAMBRIDGE, Mass., September 02, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

Yahoo·09:00

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.

Benzinga·02:23ALNY

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

Yahoo·11:56ALNY

Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says

Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success

Yahoo·12:40ALNY

Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself

Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.

Yahoo·09:48ALNY

Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and

Benzinga·04:35ALNY

Moderna's Melanoma Result Landed On A Market Positioned The Other Way

The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.

Yahoo·15:21

Biotech Is Booming, But These 2 Stocks Missed the Memo

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.

Benzinga·08:03

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention

Decent Value screen flags Alnylam Pharmaceuticals (ALNY) for strong growth, solid profitability, and reasonable forward valuation.

ChartMill·06:51ALNY

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Benzinga·03:55ALNY

BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.

Benzinga·01:30ALNY

Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis

CAMBRIDGE, Mass., August 18, 2026--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Brand

Yahoo·08:30ALNY

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.

Yahoo·07:01ALNY

Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.

Benzinga·06:43ALNY

Raymond James Is Betting Big on These 2 ‘Strong Buy’ Stocks

The S&P 500 is now sitting just below its record high, with another strong earnings season helping stocks remain near their highs. The strength has not been limited to just a handful of companies either, with most S&P 500 sectors contributing to earnings growth during the current reporting season.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new invest

Yahoo·13:55

Drugs that missed the mark in pharma’s last earnings round

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

Yahoo·06:21ALNY

American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review

U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.

SeekingAlpha·05:30

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.9% on an annualized basis producing an average annual return of 15.23%. Currently, Alnylam Pharmaceuticals has a market

Benzinga·06:00ALNY

Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options

Investors need to pay close attention to ALNY stock based on the movements in the options market lately.

Yahoo·08:30ALNY

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NE

Yahoo·16:05ALNY

Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.

Benzinga·07:28ALNY

HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $485 to $455.

Benzinga·06:54ALNY